In the last decade, a global trend of escalating ecstasy (MDMA, MDA, MDEA, MBDB) use was observed. Mentions on medical death certificates, last year's ecstasy use, number of drug offenders, seizures, prices and dosage levels figures were used for this descriptive and correlational study. Figures (1994ñ2003) were taken from the UK General Mortality Registers, from the Home Office Statistical Bulletins, from the British Crime Survey and from those reported to both the National Crime Intelligence and Forensic Science Services. A total of 394 ecstasy deaths mentions were here identified from the UK; in 42% of cases ecstasy was the sole drug mentioned. Overall, number of fatalities showed a year-peryear increase and positively correlated with: prevalence of last year's use (p<0.01); number of offenders (p<0.01) and number of seizures (p<0.01) but negatively correlated with ecstasy price (p<0.05). Price negatively correlated with: prevalence of last year's use (p<0.001) and number of seizures (p<0.01); but positively correlated with average MDMA dosage per tablet (p<0.01). MDA, MDEA and MBDB accounted for a significant proportion of tablets only up to 1997, but not afterwards. Increasing production with a concomitant decrease in ecstasy price may have facilitated an increase in consumption levels and this, in turn, may have determined an increase in number of ecstasy deaths mentions. Only medical death certificates and not coroners' reports at the end of their inquests were here analysed; no data were available in respect of other drugs use and toxicology results.
Ahmad M , Mwenda L (2004) Drug seizure and offender statistics, United Kingdom, 2001 and 2002. In Statistical Bulletin 8/04. Home Office Research Development and Statistics Directorate, London
2.
Aust R , Sharp C , Goulden C (2002) Prevalence of drug use. In Key Findings from the 2001/2 British Crime Survey. Findings 182. Home Office Research Development and Statistics Directorate, London
3.
Bellis M A , Hughes K , Bennett A , Thomson R (2003) The role of an international nightlife resort in the proliferation of recreational drugs . Addiction98: 1713–1721
4.
Bellis M A , Morleo M , Hughes S , McVeigh J , Lodwick A , Eaton G , Donnelly S (2004) Report to the EMCDDA by the Reitox National Focal Point. United Kingdom Drug Situation 2002. Department of Health, London
5.
Bramley-Harker E (2001) Sizing the UK market for illicit drugs. RDS Occasional Paper No 74. Home Office Research Development and Statistics Directorate, London
6.
Budisavljevic M N , Stewart L , Sahn S A , Ploth D W (2003) Hyponatremia associated with 3,4-methylenedioxymethylamphetamine (‘Ecstasy’) abuse . Am J Med Sci326: 89–93
7.
Christophersen O , Rooney C , Kelly S (1998) Drug-related Mortality: Methods and Trends. Population Trends No 93, Autumn 1998. Office for National Statistics, London
8.
Cole J C , Bailey M , Sumnall H R , Wagstaff G F , King L A (2002) The content of ecstasy tablets: implications for the study of their long-term effects . Addiction97: 1531–1536
9.
Corapcioglu A , Ogel K (2004) Factors associated with Ecstasy use in Turkish students . Addiction99: 67–76
10.
Corkery J M (2002) Drug seizure and offender statistics, United Kingdom, 2000, Home Office Statistical Bulletin 4/02. Home Office Research, Development and Statistics Directorate, London
11.
de la Torre R , Farre’ M , Roset P N , Hernandez Lopez C , Mas M , Ortuno J , Menoyo E , Pizarro N , Segura J , Cami J (2000) Pharmacology of MDMA in humans . Ann NY Acad Sci914: 225–237
12.
European Monitoring Centre for Drugs and Drug Addiction; EMCDDA (2004) The state of the drugs problem in the European Union and Norway. Office for Official Publications of the European Communities, Luxembourg
13.
Fallon J K , Shah D , Kicman A T , Hutt A J , Henry J A , Cowan D A , Forsling M (2002) Action of MDMA (ecstasy) and its metabolites on arginine vasopressin release . Ann N Y Acad Sci965: 399–409
14.
Forsling M L , Fallon J K , Shah D , Tilbrook G S , Cowan D A , Kicman A T , Hutt A J (2002) The effect of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus . Br J Pharmacol135: 649–656
15.
Forensic Science Service (2003) Drug Abuse Trends, publication 1994–2003. Issues 103–113 (Old Series) and Issues 1–27 (New Series). Drugs Intelligence Unit, Forensic Science Service, Birmingham
16.
Ghodse A H , Schifano F , Oyefeso A , Bannister D , Cobain K , Dryden R , Corkery J (2004) Drug-related deaths as reported by participating Procurators Fiscal and coroners in England, Wales, Northern Ireland, Scotland, Isle of Man, Guernsey and Jersey. Annual report 2004 and Surveillance Report No. 13. International Centre for Drug Policy, St George's Hospital Medical School, London
17.
Gilhooly T C , Daly A K (2002) CYP2D6 deficiency, a factor in ecstasy related deaths?Br J Clin Pharmacol54: 69–70
18.
Griffiths C (2004) Deaths related to drug poisoning: England and Wales, 1998–2002 . Hlth Stat Quart21: 59–66
19.
Helmlin H J , Bracher K , Bourquin D , Vonlanthen D , Brenneisen R (1996) Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS . J Anal Toxicol20: 432–440
20.
Henry J A , Jefferys K J , Dawling S (1992) Toxicity and deaths from 3,4-methylenedioxymethamphetamine (‘ecstasy’) . Lancet340: 384–387
21.
Hunt N (2003) Ecstasy deaths. Did alcohol play a part? BMJ.com; Available from: http://bmj.bmjjournals.com/cgi/eletters/326/7380/80
22.
Jackson G W L (2004) Drug-related Deaths in Scotland in 2003. Occasional Paper. General Register Office for Scotland, Edinburgh
23.
Landry M J (2002) MDMA: a review of epidemiological data . J Psychoactive Drugs34: 163–169
24.
Measham F , Aldridge J , Parker H (2001) Dancing on drugs: risk, health and hedonism in the British club scene. Free Association Books, London
25.
National Crime Intelligence Service (2002) Streetwise publication 1994–2002. National Criminal Intelligence Service, London
26.
Parr M J , Low H M , Botterill P (1997) Hyponatraemia and death after ‘ecstasy’ ingestion . Med J Aust166: 136–137
27.
Parrott A C (2001) Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research . Hum Psychopharmacol Clin Exp16: 557–577
28.
Parrot A C (2002) Recreational Ecstasy/MDMA, the serotinin syndrome, and serotinergic neurotoxicity . Pharmacol Biochem Behav71: 837–844
29.
Parrott A C (2004) Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity . Psychopharmacology173: 234–241
30.
Patel M M , Wright D W , Ratcliff J J , Miller M A (2004) Shedding new light on the ‘safe’ club drug: methylenedioxymethamphetamine (ecstasy)-related fatalities . Acad Emerg Med11: 208–210
31.
Ramamoorthy Y , Yu A M , Suh N , Haining R L , Tyndale R F , Sellers E M (2002) Reduced (+/-)-3,4-methylenedioxymethamphetamine (‘Ecstasy’) metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro . Biochem Pharmacol63: 2111–2119
32.
Ramsay M , Baker P , Goulden C , Sharp C , Sondhi A (2001) Drug misuse declared in 2000: results from the British Crime Survey. Home Office Research Study 224. Home Office Research Development and Statistics Directorate, London
33.
Sanjurjo E , Nogue S , Miro O , Munne P (2004) Analysis of patients attended in an emergency department due to ecstasy consumption . Med Clin (Barc)123: 90–92
34.
Schifano F (2000) Potential human neurotoxicity of MDMA (‘Ecstasy’): subjective self-reports, evidence from an Italian drug addiction centre and clinical case studies . Neuropsychobiology42: 25–33
35.
Schifano F (2001) New trends in drug addiction: synthetic drugs; epidemiological, clinical and preventative issues . Epidemiol Psich Soc10: 63–70
36.
Schifano F (2004) A bitter pill? Overview of ecstasy (MDMA; MDA) related fatalities . Psychopharmacol (Berl)173: 242–248
37.
Schifano F , Oyefeso A , Webb L , Pollard M , Corkery J , Ghodse A (2003a) Review of deaths related to taking ecstasy, England and Wales, 1997–2000 . Br Med J326: 80–81
38.
Schifano F , Oyefeso A , Corkery J , Cobain K , Jambert-Gray R , Martinotti G , Ghodse AH (2003b) Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996–2002 . Hum Psychopharmacol Clin Exp18: 519–524
39.
Segura M , Ortuno J , Farre M , McLure J A , Pujadas M , Pizarro N , Llebaria A , Joglar J , Roset P N , Segura J , de La Torre R (2001) 3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans . Chem Res Toxicoll4: 1203–1208
40.
Sumnall H R , Tyler E , Wagstaff G F , Cole J C (2004) A behavioural economic analysis of alcohol, amphetamine, cocaine and ecstasy purchases by polysubstance misusers . Drug Alcohol Depend76: 93–99
41.
Topp L , Breen C , Kaye S , Darke S (2004) Adapting the Illicit Drug Reporting System (IDRS) to examine the feasibility of monitoring trends in the markets for ‘party drugs’ . Drug Alcohol Depend73: 189–197
42.
Tucker G T , Lennard M S , Ellis S W , Woods H F , Cho A K , Lin L Y , Hiratsuka A , Schmitz D A , Chu T Y (1994) The demethylenation of methylenedioxymethamphetamine (‘ecstasy’) by debrisoquine hydroxylase (CYP2D6) . Biochem Pharmacol47: 1151–1156
43.
Wilkins C , Bhatta K , Pledger M , Casswell S (2003) Ecstasy use in New Zealand: findings from the 1998 and 2001 National Drug Surveys . N Z Med J116: U383-U383 .
44.
Yacoubian G S Jr (2003) Tracking ecstasy trends in the United States with data from three national drug surveillance systems . J Drug Ed33: 245–258
45.
Zhu B T (2002) Catechol-O-Methyltransferase (COMT)-mediated methylation-metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis . Curr Drug Metab3: 321–349
